Sun asks US FDA to withdraw nod for 28 Ranbaxy ANDAs
20 Dec 2016
Drug major Sun Pharmaceutical Industries today said one of its subsidiaries has voluntarily requested the US health regulator to withdraw approval for 28 Abbreviated New Drug Applications belonging to Ranbaxy Laboratories.
In a BSE filing, Sun Pharmaceutical Industries said, "One of the company's wholly-owned subsidiaries has voluntarily requested the US FDA to withdraw approval for 28 Abbreviated New Drug Applications (ANDAs)".
It further said, "These older drug products belong to erstwhile Ranbaxy Laboratories and are not being marketed in the US since 2008." It didn't, however, provide any details of the drugs.
In April 2014, Sun Pharma had announced the acquisition of troubled rival Ranbaxy in an all-stock transaction worth $4 billion.
Shares of Sun Pharma were trading 0.15 per cent lower at Rs 631.25 per share on BSE.
.jpg "RBI keeps repo rate unchanged as focus remains on inflation")
.jpg "Indian Oil, Panasonic team up for lithium-ion cell production in India")
